Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

95
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
95
Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

1.1K
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
1.1K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.1K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.1K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

104
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
104
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

122
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
122
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

155
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
155

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Characteristics and Outcomes in Intra-aortic Balloon Pump-Supported Cardiogenic Shock Among Patients Transferred to Tertiary Care Centers.

Journal of the Society for Cardiovascular Angiography & Interventions·2026
Same author

Aortic Pulsatility Index and Native Heart Survival in Patients With Heart Failure-Related Cardiogenic Shock.

JACC. Heart failure·2026
Same author

Trajectories and outcomes in patients with cardiogenic shock receiving heart replacement therapies.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Machine Learning-Based Phenotypes Combined with Comorbidity Burden in Cardiogenic Shock.

European journal of heart failure·2026
Same author

Outcomes Among Patients with Systolic Heart Failure and Limited English Proficiency.

Journal of immigrant and minority health·2026
Same author

Have We Been Overlooking Lipoprotein(a) in Heart Failure?

Journal of cardiac failure·2025

Related Experiment Video

Updated: Oct 29, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.4K

Phenotyping Cardiogenic Shock.

Elric Zweck1,2, Katherine L Thayer1, Ole K L Helgestad3,4

  • 1The CardioVascular Center Tufts Medical Center Boston MA.

Journal of the American Heart Association
|July 6, 2021
PubMed
Summary
This summary is machine-generated.

Machine learning identified three distinct cardiogenic shock (CS) phenotypes: non-congested, cardiorenal, and cardiometabolic. These phenotypes show unique clinical profiles and are linked to specific in-hospital mortality risks, aiding targeted treatments.

Keywords:
cardiogenic shockclustersheart failurehemodynamicsmachine learningmyocardial infarctionphenotypes

More Related Videos

Standardized Hemorrhagic Shock Induction Guided by Cerebral Oximetry and Extended Hemodynamic Monitoring in Pigs
07:51

Standardized Hemorrhagic Shock Induction Guided by Cerebral Oximetry and Extended Hemodynamic Monitoring in Pigs

Published on: May 21, 2019

7.5K
Real-time Pressure-volume Analysis of Acute Myocardial Infarction in Mice
07:28

Real-time Pressure-volume Analysis of Acute Myocardial Infarction in Mice

Published on: July 2, 2018

9.3K

Related Experiment Videos

Last Updated: Oct 29, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.4K
Standardized Hemorrhagic Shock Induction Guided by Cerebral Oximetry and Extended Hemodynamic Monitoring in Pigs
07:51

Standardized Hemorrhagic Shock Induction Guided by Cerebral Oximetry and Extended Hemodynamic Monitoring in Pigs

Published on: May 21, 2019

7.5K
Real-time Pressure-volume Analysis of Acute Myocardial Infarction in Mice
07:28

Real-time Pressure-volume Analysis of Acute Myocardial Infarction in Mice

Published on: July 2, 2018

9.3K

Area of Science:

  • Cardiology
  • Machine Learning in Medicine
  • Clinical Phenotyping

Background:

  • Cardiogenic shock (CS) is a complex syndrome with variable patient presentations and outcomes.
  • Existing approaches lack precise patient stratification for effective management.
  • Distinct patient phenotypes within CS may influence prognosis and treatment response.

Purpose of the Study:

  • To apply machine learning to identify and validate distinct patient phenotypes in cardiogenic shock.
  • To test the hypothesis that these phenotypes correlate with specific clinical characteristics and in-hospital mortality.
  • To explore the potential for phenotype-guided clinical trial enrollment and treatment strategies.

Main Methods:

  • Analysis of data from 1959 patients with CS across two international registries (CSWG and DRR).
  • Utilized consensus k-means clustering algorithm to identify patient clusters in the CSWG-MI cohort.
  • Validated identified clusters in independent CSWG-HF and DRR cohorts, categorizing by SCAI staging.

Main Results:

  • Machine learning identified three reproducible CS phenotypes: non-congested (I), cardiorenal (II), and cardiometabolic (III).
  • In-hospital mortality varied significantly across phenotypes (e.g., 10-28% for cluster I, 32-45% for cluster II, 52-56% for cluster III).
  • The cardiometabolic shock cluster exhibited the highest risk for advanced shock stages (D/E) and mortality, irrespective of etiology.

Conclusions:

  • Machine learning successfully identified and validated three distinct, reproducible cardiogenic shock phenotypes.
  • These phenotypes are associated with specific clinical profiles and mortality risks.
  • The identified phenotypes offer a basis for targeted clinical trial design and personalized therapeutic approaches in CS.